Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.36 |
| ▸ | RARG | P13631 | 4/20 | 0.36 |
| ▸ | RARA | P10276 | 3/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372175 | 0.78 | CYP26A1 (0.32) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL3300808 | 0.78 | RARB (0.56) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342902 | 0.74 | RARB (0.44) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19034054 | 0.73 | RARG (0.36) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342971 | 0.73 | RARB (0.33) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL38662534 | 0.72 | RARB (0.50) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342962 | 0.72 | RARB (0.48) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342934 | 0.72 | KDM4E (0.40) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342906 | 0.71 | RARB (0.41) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL995909 | 0.71 | CYP3A4 (0.63) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | claimed |
| US-20060205950-A1 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2006-09-14 | — | — | US | claimed |
| EP-1700855-A1 | A process for the preparation of tazarotene | SOLMAG S.p.A. (IT) | 2006-09-13 | — | — | EP | claimed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| WO-2015107542-A2 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | disclosed |
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | disclosed |
| WO-2009116075-A2 | PROCESS FOR PREPARATION OF TAZAROTENE | INDOCO REMEDIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-20060205950-A1 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2006-09-14 | — | — | US | disclosed |
| EP-1700855-A1 | A process for the preparation of tazarotene | SOLMAG S.p.A. (IT) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205950-A1 | Process for the preparation of Tazarotene | DHPS, COASY, STS | RARB 1324/4885RARG 1550/4885RARA 1663/4885 |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | PPIA, CUTA, TFPI | RARB 130/4885RARG 294/4885RARA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.